TB-500 (Thymosin Beta-4 Fragment)

Also referred to as Thymosin Beta-4 fragment, TB4 Fragment.

Status: Investigational. TB-500 is not an FDA-approved drug product, and it is not itself the full naturally occurring protein. It is a research-market name for a synthetic peptide sequence related to thymosin beta-4, a protein studied for its role in actin regulation and cell migration. "TB-500" is a designation that arose in the research-chemical marketplace rather than an approved or standardized pharmaceutical product name, and the labelling on products sold under that name is not independently verified.

TB-500 is the name used in the research-chemical marketplace for a synthetic peptide related to a short active region of thymosin beta-4, a naturally occurring protein involved in cell movement and structural signalling within cells. It is not an FDA-approved drug product, and "TB-500" itself is not a scientifically standardized name, which means products sold under it are not independently verified to contain what their labels claim. Most available evidence comes from animal studies of tissue and vascular signalling rather than controlled human trials. Patients researching it should distinguish between the biology of thymosin beta-4 as studied in labs and the unregulated commercial products marketed as TB-500.

What it is

Thymosin beta-4 is a small protein found throughout the body that plays a role in regulating actin, a structural protein involved in cell shape and movement. TB-500 refers to a synthetic peptide fragment intended to mimic part of that protein's active region, sold commercially as a research chemical. Because "TB-500" is not a regulated pharmaceutical designation, there is no standardized manufacturing specification behind the name, and the actual content of products using it can vary between suppliers.

Why people ask about it

Interest usually comes from athletes and people recovering from soft-tissue injuries who have encountered claims online linking TB-500 to recovery signalling. The naming itself causes confusion, since people often assume TB-500 is simply purified thymosin beta-4 when it is a distinct, unregulated commercial product. Patients frequently want clarity on what is actually known about thymosin beta-4 biology versus what is asserted about TB-500 specifically.

Proposed mechanism

Research on thymosin beta-4 has proposed a role in regulating actin polymerization, which affects how cells move and change shape during processes like wound closure and vascular formation. Animal studies have proposed that this could translate into effects on angiogenesis and cell migration relevant to soft-tissue and vascular models. These proposed mechanisms are derived from cell and animal work characterizing the native protein, not from pharmacology studies of the specific commercial peptide sold as TB-500. It is not established that a synthetic fragment behaves identically to the full native protein in human tissue.

What researchers have studied

• Cell-culture studies of actin regulation and cell migration
• Animal models of vascular formation (angiogenesis)
• Animal models of corneal and dermal wound closure
• Rodent models of cardiac tissue injury
• Structural and biochemical characterization of thymosin beta-4

Human evidence

• No controlled human clinical trials of the commercial product sold as TB-500 have been identified.
• Human research on the native thymosin beta-4 protein itself is limited and does not directly validate claims made about TB-500 products.
• Because product identity is not independently regulated, any anecdotal human reports cannot be tied with confidence to a verified, consistent substance.
• No human safety or exposure data specific to the commercial peptide exist in the peer-reviewed literature.

Preclinical evidence

• Rodent studies have reported effects on wound closure timelines in skin injury models.
• Animal models have reported thymosin beta-4 involvement in blood vessel formation after induced injury.
• Cell-culture work has characterized the protein's role in actin-based cell movement.
• Rodent cardiac injury models have reported changes in markers of tissue response.
• These findings are limited to laboratory and animal contexts and have not been confirmed in human trials of the commercial peptide.

What is not yet known

• Whether the commercial TB-500 product reliably matches the biology studied for native thymosin beta-4.
• Whether any human benefit exists at any exposure level.
• The consistency, purity, and identity of products sold under the TB-500 name across suppliers.
• Long-term safety of repeated exposure in people.
• How this substance might interact with other medications or conditions.
• Whether regulatory scrutiny of this substance will change as data accumulates.

Regulatory status and access

TB-500 is not offered as an individually prescribable product; where it appears in physician-directed discussion, it is only as one component a physician may consider within a broader formulation. Compounding elsewhere does not equal FDA approval, and no claim here should be read as availability. Ask about current availability. A physician determines medical appropriateness only after a full evaluation.

Known and potential risks

• No verified human safety profile exists for the specific commercial peptide sold as TB-500.
• Because the name is not a regulated designation, product identity, purity, and sterility from unregulated suppliers cannot be confirmed.
• Injection-related risks apply to any unregulated injectable research product, including contamination.
• Interaction risk with other medications or conditions is essentially unstudied.
• Marketing claims often blur the line between native thymosin beta-4 research and the unregulated commercial product, which can mislead purchasing decisions.
• Absence of oversight means adverse effects, if they occur, are unlikely to be systematically captured or reported.

Cautions and who may not be a candidate

• Pregnancy and breastfeeding, given the absence of human safety data.
• Active or suspected malignancy, given unresolved questions about cell proliferation signalling.
• Undiagnosed musculoskeletal, vascular, or cardiac symptoms that have not been medically evaluated.
• Known hypersensitivity to peptide compounds generally.
• Concurrent use of other unregulated research compounds without physician oversight.
• Use as a substitute for an evaluated, evidence-based recovery plan.

Questions to discuss with a physician

• How does the biology of thymosin beta-4 differ from claims made about commercial TB-500 products?
• What does the lack of human trial data mean for the specific concern I'm asking about?
• How would you assess the quality or legitimacy of a product marketed under this name?
• What evidence-based options exist for the recovery goal I have in mind?
• What symptoms would mean I should stop and seek care right away?
• Is there a legitimate research pathway through which this could ever become available to me?

Frequently asked questions

Is TB-500 FDA-approved?

No. TB-500 is not an FDA-approved drug product, and it is not a standardized pharmaceutical name. It refers to a synthetic peptide sold in the research-chemical marketplace.

Does GOAL.MD sell TB-500?

This page is educational only. It does not describe a product for sale. Ask about current availability, and appropriateness is determined only by a physician after evaluation.

Is TB-500 the same thing as thymosin beta-4?

TB-500 is intended to relate to an active fragment of thymosin beta-4, but it is a distinct commercial product name rather than a verified, standardized version of the native protein.

Why is it called TB-500 if that isn't a scientific name?

The designation originated in the research-chemical marketplace as a commercial label rather than through a formal pharmaceutical naming or approval process.

Has TB-500 been studied in people?

No controlled human trials of the commercial TB-500 product have been identified. Related research on the native protein exists but does not validate claims specific to commercial TB-500.

What has TB-500 been studied for in animals?

Animal and cell studies have looked at wound closure, vascular formation, and cell migration processes linked to thymosin beta-4 biology.

Is TB-500 safe?

A reliable human safety profile has not been established, and unregulated sourcing adds additional uncertainty about product identity and purity.

Can a doctor prescribe TB-500?

It is not offered as a standalone prescription product. A physician can discuss the underlying biology and any legitimate research context that might be relevant.

How do I know if a product labelled TB-500 actually contains what it claims?

There is no independent regulatory verification of these products, so label claims cannot be confirmed through standard pharmaceutical oversight.

What is TB-500?

Thymosin beta-4 is a small protein found throughout the body that plays a role in regulating actin, a structural protein involved in cell shape and movement. TB-500 refers to a synthetic peptide fragment intended to mimic part of that protein's active region, sold commercially as a research chemical. Because "TB-500" is not a regulated pharmaceutical designation, there is no standardized manufacturing specification behind the name, and the actual content of products using it can vary between suppliers.

Does the legal or regulatory status of TB-500 tell me whether it works?

No. Regulatory status describes what may lawfully be made, prescribed, or sold, and it is a separate question from what the research shows. On this page the regulatory description and the evidence tiers are kept apart so neither is mistaken for the other.

Can a licensed U.S. compounding pharmacy prepare TB-500?

TB-500 is not offered as an individually prescribable product; where it appears in physician-directed discussion, it is only as one component a physician may consider within a broader formulation. Compounding elsewhere does not equal FDA approval, and no claim here should be read as availability.

What human evidence exists for TB-500?

No published controlled human trials were identified for the uses discussed here. No controlled human clinical trials of the commercial product sold as TB-500 have been identified.

Have there been controlled human trials of TB-500?

No adequately controlled human trial for the uses discussed here was identified. Anything presented elsewhere as a human result is an extrapolation from laboratory or animal work, or an anecdote.

What have animal and laboratory studies of TB-500 reported?

Rodent studies have reported effects on wound closure timelines in skin injury models; Animal models have reported thymosin beta-4 involvement in blood vessel formation after induced injury; Cell-culture work has characterized the protein's role in actin-based cell movement. These are animal, tissue, or cell-culture findings. They describe a model, not a demonstrated result in people.

Do the animal findings for TB-500 mean it works in people?

No. Findings in animals or in cell culture routinely fail to reproduce in humans, and a positive laboratory model is not evidence of a human benefit. Whether any of this translates to people is exactly what has not been established.

How is TB-500 proposed to work?

Research on thymosin beta-4 has proposed a role in regulating actin polymerization, which affects how cells move and change shape during processes like wound closure and vascular formation. Animal studies have proposed that this could translate into effects on angiogenesis and cell migration relevant to soft-tissue and vascular models. This is a proposed pathway rather than a demonstrated effect.

What is TB-500 being studied for?

Published work has focused on Cell-culture studies of actin regulation and cell migration; Animal models of vascular formation (angiogenesis); Animal models of corneal and dermal wound closure; Rodent models of cardiac tissue injury. A research focus describes where questions are being asked, not where answers have been found.

What is still unknown about TB-500?

Whether the commercial TB-500 product reliably matches the biology studied for native thymosin beta-4; Whether any human benefit exists at any exposure level; The consistency, purity, and identity of products sold under the TB-500 name across suppliers; Long-term safety of repeated exposure in people.

What are the risks of TB-500?

No verified human safety profile exists for the specific commercial peptide sold as TB-500; Because the name is not a regulated designation, product identity, purity, and sterility from unregulated suppliers cannot be confirmed; Injection-related risks apply to any unregulated injectable research product, including contamination.

Who should not consider TB-500?

A physician would generally consider it inappropriate in these situations without specialist input: Pregnancy and breastfeeding, given the absence of human safety data; Active or suspected malignancy, given unresolved questions about cell proliferation signalling; Undiagnosed musculoskeletal, vascular, or cardiac symptoms that have not been medically evaluated; Known hypersensitivity to peptide compounds generally.

Is TB-500 appropriate during pregnancy or breastfeeding?

No. Pregnancy and breastfeeding are listed as situations where this is not appropriate, because the safety data needed to make that judgement in those populations does not exist.

How does TB-500 interact with other medications?

Interaction behaviour in people is not characterised for this substance, which is itself a reason a physician reviews the full medication list before any discussion. Interaction risk with other medications or conditions is essentially unstudied.

What would a physician monitor if TB-500 were discussed?

Monitoring concepts include Baseline evaluation of the tissue or vascular concern prompting interest; Ongoing clinical reassessment rather than reliance on unverified online reports; Discussion of any new or unexpected symptoms during any period of use. These are concepts a clinician would apply, not instructions for self-directed use.

Are products sold online as TB-500 verified?

No. Because the name is not a regulated designation, product identity, purity, and sterility from unregulated suppliers cannot be confirmed. Material bought outside a licensed pharmacy has no verified identity, purity, or sterility.

How would a GOAL.MD physician evaluate a question about TB-500?

A physician starts with the problem you are trying to solve, reviews your history and current medications, and says plainly where the evidence stands. Medical appropriateness is determined only after a full evaluation, and for many substances the honest answer is that the evidence does not support use.

What should I ask a physician about TB-500?

Useful questions include: How does the biology of thymosin beta-4 differ from claims made about commercial TB-500 products?; What does the lack of human trial data mean for the specific concern I'm asking about?; How would you assess the quality or legitimacy of a product marketed under this name?; What evidence-based options exist for the recovery goal I have in mind?.

Why do people ask about TB-500?

Interest usually comes from athletes and people recovering from soft-tissue injuries who have encountered claims online linking TB-500 to recovery signalling. The naming itself causes confusion, since people often assume TB-500 is simply purified thymosin beta-4 when it is a distinct, unregulated commercial product.

Who reviews what GOAL.MD publishes about TB-500?

Clinical content is reviewed by a named physician for medical accuracy and by a second physician for regulatory and compliance language before it is published, and a review byline appears only when that review is recorded. New material stays unpublished until both reviews are on record.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.